Your trusted source for investing success

Tag: Cannabinoids

Will Trump Bring Back the Gold Standard? Could He?

One thing is for sure, Trump is having a significant impact on the markets. Gold in particular! Get our Report (value of $49) for FREE. Limited time offer. No credit card required.   Get My Free Report
Click here to download for free

InMed Files Provisional Patent

InMed Pharmaceuticals announced the filing of a provisional patent application pertaining to the Company’s proprietary biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature.

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. to Present at 2017 Rodman & Renshaw Conference

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James

Canadian Marijuana Stocks

Canadian Marijuana Stocks

The Canadian marijuana sector is one of the hottest growing sectors. Here’s a look at Canadian cannabis companies for investors to consider.

Isodiol International Inc. Announces the Launch of Phytoceutical Division

Isodiol International Inc. Announces the Launch of Phytoceutical Division

Isodiol International Inc. (CSE:ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabinoid innovator specializing in the development of pharmaceutical and consumer products announces that it is proud to be launching a new Phytoceutical Division that will focus on cannabinoids and terpenes derived from non-cannabis sources.

Proprietary extraction methods ensure

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria’s TurboCBDTM.

Lexaria Bioscience Corporation (CSE:LXX,OTCQB:LXRP) announces the world’s first clinical study on human volunteers of cannabidiol  (CBD) within Lexaria’s high absorption TurboCBD™ product, to evaluate its effects on both cardiovascular health and cognitive function.

The study will have a double-blind and placebo controlled cross-over design measuring effects both after a single dose,

Isodiol International Inc. Provides Sponsorship At The US Autism & Asperger Association Conference

Isodiol International Inc. Provides Sponsorship At The US Autism & Asperger Association Conference

Isodiol International Inc. (CSE:ISOL) (OTC: LAGBF) (FSE: LB6A.F) (the “Company” or “Isodiol”) a global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces it proudly exhibited at the US Autism & Asperger Association (USAAA) (http://usautism.org/conferences/schedule.html) conference this past weekend in Portland, Oregon and sponsored Dr. Ronald Aung-Din to educate

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

RespireRx Pharmaceuticals Inc. Files June 30, 2017 Quarterly Report on Form 10-Q And Provides Update

RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of neurologically controlled respiratory disorders, including obstructive sleep apnea and opioid induced respiratory depression (a form of central apnea) and other respiratory and neurological conditions, has filed its June 30, 2017 Quarterly Report

Harvest One Cannabis provides Satipharm Patent Cooperation Treaty (PCT) Application update

Harvest One Cannabis provides Satipharm Patent Cooperation Treaty (PCT) Application update

Harvest One Cannabis Inc.(TSXV:HVST) is pleased to advise that the Patent Cooperation Treaty (“PCT”) application submitted by the Company’s Swiss-based subsidiary Satipharm AG (“Satipharm”) in February 2017 has now been published. This comprehensive patent application is directed at Satipharm’s proprietary Gelpell-CBD product technology, and covers oral formulations utilising both singular

"Ready to start investing in Cannabis? Get your Investor guide today"

Click below to get an INN Insider's Report on marijuana investing (value of $49) for FREE. Limited time offer. No credit card required.   Get My Free Report Click here to download 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Emerald Health Therapeutics’ Scientific Advisors Publish Research Discovery

URL: https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/emerald-health-therapeutics-scientific-advisors-publish-research-discovery/